Discure Technologies Joins FDA TAP Program for Breakthrough Degenerative Disc Disease Device
Discure Technologies, a clinical-stage medical device company pioneering treatments for degenerative disc disease and other orthopedic disorders, today announced its acceptance into the U.S. Food and Drug Administration’s (FDA) Total Product Life Cycle (TPLC) Advisory Program (TAP). Acceptance to TAP will expedite patient access to Discure’s bioelectronic implant, the Discure
